STAT+: Zealand’s GLP-2 candidate shows early weight loss results
Zealand Pharma said that its obesity candidate that uses a unique mechanism led to notable weight loss in an early trial.
Zealand Pharma said Wednesday that its obesity candidate that uses a unique mechanism led to notable weight loss in an early trial.
Over 28 weeks, patients taking dapiglutide, which targets receptors of the GLP-1 and GLP-2 hormone, lost on average 11.6% of their weight, while those on placebo lost 0.2%.
The company suggested the results were particularly promising given that 95% of the participants in the clinical trial were male. (Obesity trials usually enroll more women, who tend to lose more weight than men on medications.) Additionally, the trial did not include any lifestyle modifications.
